Literature DB >> 19409532

In vivo neuropathology of cortical changes in elderly persons with schizophrenia.

Giovanni B Frisoni1, Annapaola Prestia, Andrea Adorni, Paul E Rasser, Maria Cotelli, Andrea Soricelli, Matteo Bonetti, Cristina Geroldi, Panteleimon Giannakopoulos, Paul M Thompson.   

Abstract

BACKGROUND: Elderly schizophrenia patients frequently develop cognitive impairment of unclear etiology. Magnetic resonance imaging (MRI) studies revealed brain structural abnormalities, but the pattern of cortical gray matter (GM) volume and its relationship with cognitive and behavioral symptoms are unknown.
METHODS: Magnetic resonance scans were taken from elderly schizophrenia patients (n = 20, age 67 +/- 6 SD, Mini-Mental State Examination [MMSE] 23 +/- 4), Alzheimer's disease (AD) patients (n = 20, age 73 +/- 9, MMSE 22 +/- 4), and healthy elders (n = 20, age 73 +/- 8, MMSE 29 +/- 1). Patients were assessed with a comprehensive neuropsychological and behavioral battery. Cortical pattern matching and a region-of-interest analysis, based on Brodmann areas (BAs), were used to map three-dimensional (3-D) profiles of differences in patterns of gray matter volume among groups.
RESULTS: Schizophrenia patients had 10% and 11% lower total left and right GM volume than healthy elders (p < .001) and 7% and 5% more than AD patients (p = .06 and ns). Regions that had both significantly less gray matter than control subjects and gray matter volume as low as AD mapped to the cingulate gyrus and orbitofrontal cortex (BA 30, 23, 24, 32, 25, 11). The strongest correlate of gray matter volume in elderly schizophrenia patients, although nonsignificant, was the positive symptom subscale of the Positive and Negative Syndrome Scale, mapping to the right anterior cingulate area (r = .42, p = .06).
CONCLUSIONS: The orbitofrontal/cingulate region had low gray matter volume in elderly schizophrenia patients. Neither cognitive impairment nor psychiatric symptoms were significantly associated with structural differences, even if positive symptoms tended to be associated with increased gray matter volume in this area.

Entities:  

Mesh:

Year:  2009        PMID: 19409532     DOI: 10.1016/j.biopsych.2009.02.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Reduced middle cingulate gyrus volume in late-onset schizophrenia in a Chinese Han population: a voxel-based structural MRI study.

Authors:  Hong Li; Jinsong Tang; Liping Chen; Yanhui Liao; Bing Zhou; Ying He; Zongchang Li; Luxian Lv; Yi Zeng; Xiaogang Chen
Journal:  Neurosci Bull       Date:  2015-05-08       Impact factor: 5.203

2.  Abnormalities in cortical gray matter density in borderline personality disorder.

Authors:  R Rossi; M Lanfredi; M Pievani; M Boccardi; P E Rasser; P M Thompson; E Cavedo; M Cotelli; S Rosini; R Beneduce; S Bignotti; L R Magni; L Rillosi; S Magnaldi; M Cobelli; G Rossi; G B Frisoni
Journal:  Eur Psychiatry       Date:  2015-01-02       Impact factor: 5.361

3.  Resilient protein co-expression network in male orbitofrontal cortex layer 2/3 during human aging.

Authors:  Mohan Pabba; Enzo Scifo; Fenika Kapadia; Yuliya S Nikolova; Tianzhou Ma; Naguib Mechawar; George C Tseng; Etienne Sibille
Journal:  Neurobiol Aging       Date:  2017-07-05       Impact factor: 4.673

4.  Hippocampal and amygdalar local structural differences in elderly patients with schizophrenia.

Authors:  Annapaola Prestia; Enrica Cavedo; Marina Boccardi; Cristina Muscio; Andrea Adorni; Cristina Geroldi; Matteo Bonetti; Paul M Thompson; Giovanni B Frisoni
Journal:  Am J Geriatr Psychiatry       Date:  2014-01-22       Impact factor: 4.105

5.  Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders.

Authors:  Victor Vostrikov; Natalya Uranova
Journal:  Schizophr Res Treatment       Date:  2011-07-03

Review 6.  Can neurostimulation prevent the risk of Alzheimer's disease in elderly individuals with schizophrenia?

Authors:  Adonis Sfera
Journal:  Front Psychiatry       Date:  2013-09-18       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.